Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.51 |
| ▸ | FLT1 | P17948 | 6/20 | 0.51 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837590 | 1.00 | KDR (0.51) | KDRFLT1METSCN9AADORA2A | |
| SCHEMBL5838484 | 1.00 | KDR (0.51) | KDRFLT1METSCN9AADORA2A | |
| SCHEMBL6747147 | 0.91 | KDR (0.54) | KDRFLT1METHRH3 | |
| SCHEMBL5839374 | 0.89 | KDR (0.46) | KDRFLT1METSCN9A | |
| SCHEMBL5838954 | 0.89 | KDR (0.46) | KDRFLT1METSCN9A | |
| SCHEMBL5838689 | 0.89 | KDR (0.46) | KDRFLT1METSCN9A | |
| SCHEMBL5838964 | 0.89 | KDR (0.46) | KDRFLT1METSCN9A | |
| SCHEMBL5771691 | 0.85 | KDR (0.50) | KDRFLT1METSCN9AADORA2A | |
| SCHEMBL5771679 | 0.85 | KDR (0.50) | KDRFLT1METSCN9AADORA2A | |
| SCHEMBL6752148 | 0.84 | KDR (0.49) | KDRFLT1METADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995171-B2 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | claimed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | claimed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6995171-B2 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-6833456-B2 | Heterocyclic sulfides such as 5-(2-(2R-Hydroxymethyl-pyrrolidine-1-carbonyl)-thieno(3,2-b)pyridin-7 -ylamino)-2-methyl-indole-1-carboxylic acid methylamide, used as angiogenesis inhibitors | AGOURON PHARMACEUTICALS, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | ROMINES WILLIAM HENRY (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | TK1, TYMP, DPYD | KDR 1886/4885FLT1 606/4885MET 3998/4885 |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | CDKN1A, CCNA1, TYMP | KDR 62/4885FLT1 12/4885MET 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.